Merck & Co. 10-Qquarter ended 2026-06-30

Executive Summary

Merck grew sales 5% in Q2 2026 as newer medicines and Animal Health offset declining diabetes and infectious-disease products. Its GAAP loss reflects a deliberate, unusually large pipeline investment: the Cidara and Terns acquisitions generated $14.7B of acquired-research charges in H1, overwhelming growth in the operating segments. Operating cash flow exceeded the reported loss by a wide margin, but acquisition spending reduced liquidity and increased borrowing costs. For investors, the question is whether new products and the acquired pipeline can replace revenue exposed to patent expirations and pricing pressure before those investments deliver returns.

Key Financial Highlights

• Margin and expenses: Gross margin fell to 73.5% from 77.5% in Q2, reflecting higher intangible amortization, inventory charges and restructuring; R&D rose to $9.74B from $4.05B, principally because of acquired pipeline assets.
• Earnings quality: H1 operating cash flow rose from $5.79B despite the GAAP loss; its reconciliation included $13.8B of adjustments for research-asset acquisitions. Capital expenditures were $1.88B.
• Capital allocation: H1 repurchases totaled $1.6B for 14M shares, but shares outstanding fell by only 6M net, from 2.475B to 2.469B. Dividends paid were $4.25B.
• Financing and tax: Q2 interest expense rose to $525M from $305M. The tax provision despite pretax losses produced a Q2 effective tax rate of (95.9)%, chiefly because acquisition charges provided no tax benefit.

Business Developments

Merck’s growth mix is shifting, though Keytruda remains dominant. Combined Keytruda and Keytruda Qlex sales reached $8.37B in Q2, up from $7.96B; the established Keytruda product alone declined slightly. Winrevair grew to $588M from $336M, Welireg to $271M from $162M, and Ohtuvayre contributed $204M following the 2025 Verona acquisition. Animal Health sales rose 8% to $1.78B. These gains contrasted with declining Januvia/Janumet sales and weak H1 Gardasil demand, particularly in China and Japan.

Merck paid $9.2B for Cidara and $6.8B for Terns to add influenza-prevention and oncology candidates. Management is allocating substantial capital toward future products rather than current earnings; Cidara’s lead candidate is in Phase 3, while Terns’ is in Phase 1/2. July’s ≈$650M TARGAN acquisition extends Animal Health into poultry technology. Restructuring charges totaled $800M in H1 as Merck pursues savings, while Blackstone funding reduced H1 R&D expense by $400M in exchange for potential royalties. Pipeline results were mixed: tulisokibart reported positive Phase 3 ulcerative-colitis data, but two other studies are being discontinued.

Risk Assessment

• Product concentration and exclusivity: Keytruda remains the largest sales driver, while U.S. exclusivity ended for Januvia and Janumet in May and Janumet XR in July; further generic entry and patent disputes threaten established revenue.
• Acquisition execution: $14.7B of H1 acquired-research charges relate to candidates still facing clinical and commercial uncertainty, so spending may not produce replacement sales.
• Pricing and demand: U.S. negotiated drug prices, international reimbursement pressure and weak Gardasil demand in China constrain growth; H1 China sales fell to $797M from $1.15B.
• Liquidity and borrowing costs: Acquisition outflows reduced cash and investments while long-term debt and interest expense rose, narrowing flexibility for further investment and shareholder returns.
• Tax and litigation: The Internal Revenue Service proposes ≈$1.3B of additional transition tax plus $260M in penalties, excluding interest; Merck disputes the adjustment and also faces continuing product and other litigation.
• Margin pressure: Higher amortization, inventory charges and restructuring costs reduced gross margin even as revenue grew, making sales growth a less reliable indicator of near-term earnings.

A 10-Q does not have to restate the risk factors in the annual report. Full list: FY2025 10-K.

Strategic Outlook and Investor Actionables

Merck is using near-term earnings and balance-sheet capacity to broaden its future portfolio. New-product uptake offers a path beyond maturing franchises, but the investment case depends on sustained commercial adoption, clinical progress and a recovery in margins.

• Track Keytruda/Keytruda Qlex, Winrevair and Ohtuvayre sales against Januvia/Janumet erosion; sustained combined growth would support the portfolio-transition thesis.
• Track gross margin and restructuring charges; improvement would show whether savings and product mix are beginning to offset acquisition-related costs.
• Track operating cash flow, cash and investments, and long-term debt; stabilization would indicate that pipeline investment and shareholder returns remain financeable without further balance-sheet deterioration.